The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality
Open accessThe DOI matches its Crossref record; 374 of the 377 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Liver diseases have become a major health threat across Europe, and the face of European hepatology is changing due to the cure of viral hepatitis C and the control of chronic viral hepatitis B, the increasingly widespread unhealthy use of alcohol, the epidemic of obesity, and undiagnosed or untreated liver disease in migrant populations.Consequently, Europe is facing a looming syndemic, in which socioeconomic and health inequities combine to adversely affect liver disease prevalence, outcomes, and opportunities to receive care.In addition, the COVID-19 pandemic has magnified pre-existing challenges to uniform implementation of policies and equity of access to care in Europe, arising from national borders and the cultural and historical heterogeneity of European societies.In following up on work from the Lancet Commission on liver disease in the UK and epidemiological studies led by the European Association for the Study of the Liver (EASL), our multidisciplinary Commission, comprising a wide range of public health, medical, and nursing specialty groups, along with patient representatives, set out to provide a snapshot of the European landscape on liver diseases and to propose a framework for the principal actions required to improve liver health in Europe.We believe that a joint European process of thinking, and construction of uniform policies and action, implementation, and evaluation can serve as a powerful mechanism to improve liver care in Europe and set the way for similar changes globally.On the basis of these data, we present ten actionable recommendations, half of which are oriented towards health-care providers and half of which focus primarily on health policy.A fundamental shift must occur, in which health promotion, prevention, proactive casefinding, early identification of progressive liver fibrosis, and early treatment of liver diseases replace the current emphasis on the management of end-stage liver disease complications.A considerable focus should be put on underserved and marginalised communities, including early diagnosis and management in children, and we provide proposals on how to better target disadvantaged communities through health promotion, prevention, and care using multilevel interventions acting on current barriers.Underlying this transformative shift is the need to enhance awareness of the preventable and treatable nature of many liver diseases.Therapeutic nihilism, which is prevalent in current clinical practice across a range of medical specialities as well as in many patients themselves, has to end.We wish to challenge medical specialty protectionism and invite a broad range of stakeholders, including primary care physicians, nurses, patients, peers, and members of relevant communities, along with medical specialists trained in obesity, diabetes, liver disease, oncology, cardiovascular disease, public health, addictions, infectious diseases, and more, to engage in integrated person-centred liver patient care across classical medical specialty boundaries.This shift includes a revision in how we converse about liver disease and speak with our patients, and a reappraisal of disease-related medical nomenclature conducted to increase awareness and reduce the social stigmatisation associated with liver disease.Reimbursement mechanisms and insurance systems must be harmonised to account for patient-centric, multimorbidity models of care across a range of medical specialties, and the World Health Assembly resolution to improve the transparency and fairness of market prices for medicines throughout Europe should be reinforced.Finally, we outline how Europe can move forward with implementation of effective policy action on taxation, food reformulation, and product labelling, advertising, and availability, similar to that implemented for tobacco, to reduce consumption of alcohol, ultraprocessed foods, and foods with added sugar, especially among young people.We should utilise the window of opportunity created by the COVID-19 pandemic to overcome fragmentation and the variability of health prevention policies and research across Europe.We argue that the liver is a window to the 21st-century health of the European population.Through our proposed syndemic approach to liver disease and social and health inequities in Europe, the liver will serve as a sentinel for improving the overall health of European populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The greatest unmet needs reside with PSC, which poses a significant disease burden both for the affected individuals and the healthcare sector.465”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [465]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Vos, T., Lim, S. S., Abbafati, C., Abbas, K. M., Abbasi, M., Abbasifard, M., Abbasi-Kangevari, M., Abbastabar, H., Abd-Allah, F., Abdelalim, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30925-9 · Cited by 19,358
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Self-citationFood in the Anthropocene: the EAT–Lancet Commission on healthy diets from sustainable food systems
Willett, W., Rockström, J., Loken, B., Springmann, M., Lang, T., Vermeulen, S., Garnett, T., Tilman, D., DeClerck, F., Wood, A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31788-4 · Cited by 10,880
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Forner, A., Reig, M., & Bruix, J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30010-2 · Cited by 5,531
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
Lampertico, P., Agarwal, K., Berg, T., Buti, M., Janssen, H. L. A., Papatheodoridis, G., Zoulim, F., & Tacke, F. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.021 · Cited by 5,391
Self-citationEASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Self-citation
Research works printed but not linked: 7
- Sze, 2020, Ethnicity and clinical outcomes in COVID-19: a systematic review and meta-analysis, EClinicalMedicine, 29
- Tan, 2020, Obesity and covid-19: the role of the food industry, BMJ, 369
- Harrison, 2016, Assessment and management of cirrhosis in people older than 16 years: summary of NICE guidance, BMJ, 354
- Boettler, 2020, Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper, JHEP Rep, 2
- Burton, 2017, A rapid evidence review of the effectiveness and cost-effectiveness of alcohol control policies: an English perspective, Lancet, 389, 1558, 10.1016/s0140-6736(16)32420-5 · DOI · Paper page
- Chaillon, 2019, Cost-effectiveness of universal hepatitis C virus screening of pregnant women in the United States, Clin Infect Dis, 69, 1888, 10.1093/cid/ciz063 · DOI
- Heffernan, 2019, Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model, Lancet, 393, 1319, 10.1016/s0140-6736(18)32277-3 · DOI · Paper page
Cited by
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
“Such cases and also cryptogenic cases that subsequently manifest CMRF can be rebadged as MASLD.”
Self-citationA multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.06.003 · Cited by 3,100
Self-citationGlobal burden of liver disease: 2023 update
Devarbhavi, H., Asrani, S. K., Arab, J. P., Nartey, Y. A., Pose, E., & Kamath, P. S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.017 · Cited by 2,267
Self-citationTacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
Self-citationLane, M. M., Gamage, E., Du, S., Ashtree, D. N., McGuinness, A. J., Gauci, S., Baker, P., Lawrence, M., Rebholz, C. M., Srour, B., et al. (2024) · BMJ · doi:10.1136/bmj-2023-077310 · Cited by 1,153
Metadata
- Authors
- Karlsen, T. H., Sheron, N., Zelber-Sagi, S., Carrieri, P., Dusheiko, G., Bugianesi, E., Pryke, R., Hutchinson, S. J., Sangro, B., Martin, N. K., Cecchini, M., Dirac, M. A., Belloni, A., Serra-Burriel, M., Ponsioen, C. Y., Sheena, B., Lerouge, A., Devaux, M., Scott, N., Hellard, M., Verkade, H. J., Sturm, E., Marchesini, G., Yki-Järvinen, H., Byrne, C. D., Targher, G., Tur-Sinai, A., Barrett, D., Ninburg, M., Reic, T., Taylor, A., Rhodes, T., Treloar, C., Petersen, C., Schramm, C., Flisiak, R., Simonova, M. Y., Pares, A., Johnson, P., Cucchetti, A., Graupera, I., Lionis, C., Pose, E., Fabrellas, N., Ma, A. T., Mendive, J. M., Mazzaferro, V., Rutter, H., Cortez-Pinto, H., Kelly, D., Burton, R., Lazarus, J. V., Ginès, P., Buti, M., Newsome, P. N., Burra, P., & Manns, M. P.
- Affiliations
- Oslo University Hospital (NO)
- King's College London (GB)
- University of Haifa (IL)
- Inserm (FR)
- King's College Hospital (GB)
- University of Turin (IT)
- Glasgow Caledonian University (GB)
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES)
- University of Bristol (GB)
- Organisation de Coopération et de Développement Economiques (FR)
- University of Washington (US)
- Public Health England (GB)
- Amsterdam UMC Location University of Amsterdam (NL)
- Burnet Institute (AU)
- University Medical Center Groningen (NL)
- University Children's Hospital Tübingen (DE)
- IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
- University of Helsinki (FI)
- University of Verona (IT)
- University of Gothenburg (SE)
- Childrens Liver Disease Foundation (GB)
- London School of Hygiene & Tropical Medicine (GB)
- UNSW Sydney (AU)
- Medizinische Hochschule Hannover (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- Medical University of Białystok (PL)
- Military Medical Academy (BG)
- Hospital Clínic de Barcelona (ES)
- University of Liverpool (GB)
- University of Bologna (IT)
- University of Crete (GR)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Instituto de Salud Carlos III (ES)
- University of Milan (IT)
- University of Bath (GB)
- Birmingham Women's Hospital (GB)
- University Hospitals Birmingham NHS Foundation Trust (GB)
- Azienda Ospedale - Università Padova (IT)
- Corresponding author
- Karlsen, Tom H
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2022-01
- Volume
- 399
- Issue
- 10319
- Pages
- 61-116
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4200536452
- Cited by
- 652
- References
- 377
- Citations by year
- 2026: 96 · 2025: 168 · 2024: 147 · 2023: 142 · 2022: 94
- FWCI
- 14.85
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- ePrints Soton (University of Southampton) (acceptedVersion)
- ResearchOnline (Glasgow Caledonian University) (acceptedVersion, cc-by-nc-nd)
- Pure (University of Bath) (submittedVersion, cc-by-nc-nd)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by-nc-nd)
- Deposito Adademico Digital Universidad De Navarra (University of Navarra) (submittedVersion, other-oa)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, cc-by-nc-nd)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion)
- UNSWorks (UNSW Sydney) (submittedVersion, cc-by)
- NORA - Norwegian Open Research Archives (submittedVersion, cc-by-nc-nd)
- Padua Research Archive (University of Padova) (submittedVersion, cc-by-nc-sa)
- Funders
- European Commission
- French National Research Agency
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- liver disease, health disparities, liver fibrosis, early diagnosis, liver disease prevention, health promotion, migrants, obesity, alcohol consumption, viral hepatitis, COVID-19 pandemic, therapeutic nihilism, person-centred care, multidisciplinary care, Europe
- MeSH terms
- Europe, Health Policy, Humans, Liver Diseases, Mortality, Premature
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. https://app.cochat.ai/papers/10.1016/s0140-6736(21)01701-3
- The paper
- Karlsen, T. H., Sheron, N., Zelber-Sagi, S., Carrieri, P., Dusheiko, G., Bugianesi, E., Pryke, R., Hutchinson, S. J., Sangro, B., Martin, N. K., Cecchini, M., Dirac, M. A., Belloni, A., Serra-Burriel, M., Ponsioen, C. Y., Sheena, B., Lerouge, A., Devaux, M., Scott, N., . . . Manns, M. P. (2022). The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. The Lancet. https://doi.org/10.1016/s0140-6736(21)01701-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.